Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report
- 6 August 2021
- journal article
- research article
- Published by International Scientific Information, Inc. in The American Journal of Case Reports
- Vol. 22, e932924
- https://doi.org/10.12659/AJCR.932924
Abstract
Objective: Unusual clinical course Background: The efficacy and safety of re-challenge with immune checkpoint inhibitors after immune-related adverse events have not been established. We report a case of successful re-administration of nivolumab in metastatic renal cell carcinoma after discontinuation due to immune-related adverse events. Case Report: Laparoscopic nephrectomy was performed on a 52-year-old man diagnosed with renal cell carcinoma pT1bN0M0. After surgery, left adrenal and lung metastases appeared. Nivolumab was administered as a sixth-line therapy, and he achieved a partial response, but interstitial pneumonia occurred. He was diagnosed with grade 2 immune-related adverse events, and nivolumab treatment was discontinued. Interstitial pneumonia was well controlled by steroids. He maintained a partial response for a long time, and the lung metastases disappeared 7 months after discontinuation. However, bilateral lung metastases reappeared 10 months after the discontinuation. We decided to re-administer nivolumab, while carefully monitoring the patient and fully explaining the risk of recurrence of immune-related adverse events. After 5 cycles of re-administration, computed tomography revealed a reduction in metastases without re-activation of interstitial pneumonia. He experienced a grade 1 fever the day after re-administration, but continued nivolumab therapy without other adverse events. After 7 cycles of re-administration, the lung metastases increased, and nivolumab treatment was terminated. Two months later, a grade 2 interstitial pneumonia recurred, but improved rapidly with oral steroids. Conclusions: For patients who have discontinued immune checkpoint inhibitors due to immune-related adverse events, rechallenge of immune checkpoint inhibitors may be an option after explaining the risk of relapse of immune-related adverse events.This publication has 11 references indexed in Scilit:
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaJAMA Oncology, 2020
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020Journal of the National Comprehensive Cancer Network, 2020
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinomaJournal for ImmunoTherapy of Cancer, 2019
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated ColitisJournal of Clinical Oncology, 2019
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2019
- Novel patterns of response under immunotherapyAnnals of Oncology, 2019
- Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCCancer Immunology Research, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010